The effect of sub-inhibitory concentrations of 16 antibacterials on the bactericidal activity of the 4-quinolones nalidixic acid, ciprofloxacin and ofloxacin against Escherichia coli KL16 in nutrient broth was investigated. Sub-inhibitory concentrations of rifampicin, clindamycin, chloramphenicol, erythromycin or tetracycline antagonised the bactericidal activity of the 4-quinolones. Conversely, all seven aminoglycosides tested enhanced the bactericidal activity of the 4-quinolones whereas the cell wall antagonists, azlocillin, mezlocillin, ceftazidime and vancomycin had no effect on the bactericidal activity of the 4-quinolones.
Introduction
MIC (minimum inhibitory concentration) studies suggest that little interaction occurs between the 4-quinolones and other antibacterials (Neu and Labthavikul, 1982; Van der Auwera, 1985; Davies and Cohen, 1985; Wolfson and Hooper, 1985; Smith et al., 1986) . However, MICs provide information only about the inhibition of bacterial multiplication and provide no information on the bacterial killing process (Smith, 1984) which may be important in neutropenic patients. As protein and RNA synthesis are known to be prerequisites for the full bactericidal activity of the 4-quinolones (Dietz et al., 1966; Smith, 1984) , it is not surprising that the protein synthesis inhibitor chloramphenicol and the RNA synthesis inhibitor rifampicin have been found to antagonise the bactericidal activity of the 4-quinolones (Smith, 1984) although they do not affect the bacteriostatic activity of the 4-quinolones. The effects of sub-inhibitory concentrations of 16 different antibacterials on the bactericidal activity of nalidixic acid, ciprofloxacin and ofloxacin against Escherichia coli KLl6 in nutrient broth were therefore investigated.
Materials and methods

Antibacterials
The following antibacterial agents were obtained from the indicated suppliers : amikacin (Bristol Laboratories), azlocillin (Bayer), ceftazidime (Glaxo), chloramphenicol Received 24 Aug. 1988 (Parke-Davis), ciprofloxacin (Bayer), clindamycin (Upjohn), erythromycin (Eli Lilly and Co.), gentamicin (Roussel Laboratories), kanamycin (Bristol Laboratories), mezlocillin (Bayer), nalidixic acid (Sterling-Winthrop), netilmicin (Schering Corporation), ofloxacin (Hoeschst), rifampicin (Merrell Dow Pharmaceuticals), sisomicin (Schering Corporation), streptomycin (Evans Medical Ltd), tetracycline (Lederle Laboratories), tobramycin and vancomycin (Eli Lilly and Co.).
All except erythromycin, nalidixic acid, ofloxacin and rifampicin were dissolved in sterile distilled water. Rifampicin and erythromycin were dissolved in absolute alcohol or dimethyl sulphoxide. Nalidixic acid and ofloxacin were first dissolved in 0-5 M NaOH (0.02 ml/ mg) before being diluted to appropriate concentrations in sterile distilled water.
Determination of bactericidal activity
The 4-quinolones cause filamentation of bacteria, which increases the turbidity of liquid cultures, so bacterial killing by the 4-quinolones cannot be judged by light scattering or optical density measurements (Smith, 1984) . The bactericidal activity of the 4-quinolones studied was measured therefore by determining viable counts.
Nutrient Broth No. 2 (Oxoid) was inoculated with E. coli KL16 and incubated overnight at 37°C.
Sterile double strength nutrient broth (5 ml) was added to the aqueous drug (or drugs) and the volume was made up to 9.8 ml with sterile distilled water. The antimicrobial solutions were incubated at 37°C for at least 15 min and then 0.2 ml of an overnight culture of E. coli KL16 which contained c. 5 x lo8 cfu/ml was added at time zero to complete the reaction mixtures. The viable count at time zero was c. lo7 cfu/ml. At 30-min intervals, 0-1-ml samples from each reaction mixture were taken and serial 10-fold dilution were made in sterile nutrient broth. A 0-1-ml sample of each dilution was plated on to nutrient agar and the number of colonies was counted after incubation overnight at 37°C. The results obtained were used to calculate the 99% kill time against E. coli KL16 of the 4-quinolone with and without a sub-inhibitory concentration of a second antibacterial. chloramphenicol reduced the bactericidal activity of ciprofloxacin and totally inhibited the bactericidal activity of nalidixic acid against E. coli KL16 in nutrient broth. When sub-inhibitory concentrations of these two drugs were combined with nalidixic acid 50 mg/L or ciprofloxacin 0.01 5 mg/L the time taken to kill 99% of the E. coli KL16 in nutrient broth was greater than when the 4quinolones were used alone (tables I and 11).
Results
Bacteriostatic concentrations of rifampicin or Sub-inhibitory concentrations of three other inhibitors of protein synthesis, tetracycline 0.03 mg/L, erythromycin 30 mg/L and clindamycin 10mg/L were also tested for their effect on the bactericidal activity of the 4-quinolones. All three antibacterials increased the 99% kill times of nalidixic acid 50mg/L ( fig. 1 and table I) and of ciprofloxacin 0.0 15 mg/L ( fig. 1 and table 11 ) against E. coli KL16 in nutrient broth. The bactericidal activity of the two 4-quinolones appears, therefore, side streptomycin (2 mg/L). The effect was progressive with the bactericidal activity of nalidixic acid 50 mg/L being increasingly enhanced by streptomycin 2 mg/L over 7 h (fig. 3) .
The bactericidal activities of nalidixic acid fig. 4 and table 11) were also enhanced by a sub-inhibitory concentration of the D-aminoglycoside tobramycin (0.4 mg/L). When a further five aminoglycosides were tested they also enhanced the bactericidal activity of nalidixic acid 50 mg/L (table I) and of ciprofloxacin 0.015 mg/L (table 11) against E. coli KL16 in nutrient broth. Therefore, the aminoglycosides appear to enhance the bactericidal activity of ciprofloxacin and nalidixic acid, whereas the other protein synthesis inhibitors antagonise the 4-quinolone bactericidal activity. A beneficial interaction often occurs between two antibacterials when the drug concentrations are sub-optimal rather than optimal. However, sisomicin 0.4 mg/L was not only able to enhance the bactericidal activity of ciprofloxacin 0.01 5 mg/ L against E. coli KL16 but when ciprofloxacin was used at its maximum bactericidal concentration of 0-15 mg/L, potentiation still occurred ( fig. 5) . Hence, even the optimal bactericidal activity of the 4-quinolones was enhanced by the aminoglycosides.
The interactions of the two 4-quinolones with sub-inhibitory concentrations of inhibitors of cellwall synthesis, including vancomycin which has already been used in combination with ciprofloxacin (Smith et al., 1988) , were also examined. Vancomycin at a sub-inhibitory concentration of 0.4 mg/L had no effect on the bactericidal activity of either nalidixic acid 50 mg/L or of ciprofloxacin 0.015 mg/L against E. coli KL16 in nutrient broth ( fig. 6 and tables I and 11) . The bactericidal activities of nalidixic acid 50 mg/L or of ciprofloxacin 0.015 mg/L against E. coli KL16 in nutrient broth were also found to be unaffected by subinhibitory concentrations of the p-lactam cell-wall antagonists, ceftazidime, azlocillin and mezlocillin (tables I and 11). Therefore, the bactericidal activity of the two 4-quinolones against E. coli KL16 appeared to be unaffected by sub-inhibitory concentrations of p-lactams or vancomycin. The effects of sub-inhibitory concentrations of the same 16 antibacterials were also tested on a third 4-quinolone, ofloxacin. Sub-inhibitory concentrations of all seven aminoglycosides tested enhanced the bactericidal activity of ofloxacin 0.06 mg/L against E. coli KL16 in nutrient broth (table 111) ; all the 99% kill times were reduced. Conversely, sub-inhibitory concentrations of the other inhibitors of protein and RNA synthesis tested (rifampicin, tetracycline, chloramphenicol, erythromycin and clindamycin) increased the time required by ofloxacin 0.06 mg/L to kill 99% of the E. coli (table 11) and hence antagonise the bacteri- cidal activity of the 4-quinolone. As with ciproflox-Tai and Davis, 1985) . It has been suggested that acin and nalidixic acid, the four cell-wall this damage caused to the bacterial membrane by antagonists tested had no effect on the bactericidal the aminoglycosides offers an explanation for these activity of ofloxacin against E. coliKL16 in nutrient drugs being bactericidal against E. coli in contrast broth. The results obtained with ofloxacin were, to chloramphenicol, tetracycline and erythromycin therefore, similar to those obtained with ciproflox-which are merely bacteriostatic (Tanaka, 1982; acin and nalidixic acid. Tanaka et al., 1984) . The interaction between the aminoglycosides and the bacterial membrane would also seem to provide a possible explanation for the aminoglycosides forming a distinct sub-group Discussion
The 16 antibacterials that were investigated for amongst the inhibitors of protein synthesis in their their effect on the bactericidal activities of cipro-interaction with the 4-quinolones. The membrane floxacin, nalidixic acid and ofloxacin against E.-coZi KL16 in nutrient broth can be divided into three groups : firstly, the RNA synthesis inhibitor rifampicin and the protein synthesis inhibitors, tetracycline, erythromycin, clindamycin and c hloramp henicol, that antagonised the bactericidal activity of the 4-quinolones ; secondly, the aminoglycosides that enhanced 4-quinolone bactericidal activity; and thirdly the cell-wall antagonists that had no effect on 4-quinolone bactericidal activity. The aminoglycosides also enhanced the optimal bactericidal activity of the 4-quinolones. This is not always the case with combinations of antimicrobials, as enhancement may only occur at suboptimal drug concentrations, e.g., combinations of trimethoprim and sulphonamide (Amyes, 1982) .
Unlike the other inhibitors of protein and RNA synthesis tested, the aminoglycosides damage the bacterial membrane (Tanaka, 1982; Davis, 1987) . This is a secondary effect related to inhibition of protein synthesis, the addition of chloramphenicol having been shown to eliminate the membrane damage caused by streptomycin (Tanaka, 1982;  damage caused by the -aminoglycosides, which is thought to be due to the incorporation of misread proteins into the membrane, increases the permeability of the membrane (Davis et al., 1986; Davis, 1987) and also interferes with the initiation step of DNA synthesis (Tanaka et al., 1984) , probably by interfering with the formation of the oriC-membrane complex (Matsunaga et al., 1986) . These changes in membrane permeability may increase 4-quinolone uptake. Alternatively, the aminoglycosides may act via their effect on the initiation of DNA replication because the 4-quinolones also affect the replication of DNA. The observation that sub-inhibitory concentrations of aminoglycosides enhance the killing activity of the 4-quinolones, but not vice versa (Lewin, 1987) , suggests that the first hypothesis is more probable. However, further investigation is necessary to identify the mechanism by which the aminoglycosides enhance 4-quinolone bactericidal activity .
Other workers have also demonstrated synergy between aminoglycosides and ciprofloxacin in vitro (Chalkley and Koornhof, 1985) . It is interesting to note that combinations of some cell wall antagonists and ciprofloxacin have been found to be synergic against Pseudomonas aeruginosa in vivo as well as in vitro (Chalkley and Koornhof, 1985 ; Giamarellou and Petrikkos, 1987; Fu et al., 1987; Bustamente et al., 1987) . Hence it is possible that the cell wall antagonists may, in some cases, act synergically with the 4-quinolones rather than the combination being additive or indifferent. However, no antagonism of the bactericidal activity of the 4-quinolones by the cell wall antagonists has been reported. In conclusion, investigations on the effect of subinhibitory concentrations of other antibacterials on the bactericidal activity of nalidixic acid, ciprofloxacin and ofloxacin against E. coli KL16 in nutrient broth showed no antagonism between the 4quinolones and cell wall antagonists. The aminoglycosides were found to form a distinct subgroup amongst the inhibitors of protein or RNA synthesis tested as the former enhanced the bactericidal activity of the 4-quinolones whilst the latter antagonised their bactericidal activity. Matsunaga K, Yamaki H, Nishimuro T, Tanaka N 1986 Inhibition of DNA replication initiation by aminoglycoside antibiotics. Antimicrobial Agents and Chemotherapy30: 468-474. Neu H C, Labthavikul P 1982 
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